Animal Modeling and Preclinical Therapeutics Core in this P01 will use genetically engineered mouse (GEM) models of lung cancer, standard lung cancer cell line xenografts, and patient-derived lung cancer xenografts (PDXs) to facilitate the identification of the most effective tool compounds and combination(s) of compounds in the treatment of the genotype-specific stratified lung cancers studied in each of the projects. This core will provide technical and scientific expertise for in vivo experiments for each project in the program and allow the collective efforts of each of the three projects to focus more on the mechanistic studies to identify the best combination of compounds to maximize therapeutic efficacy. GEM models of lung cancers based on specific oncogenic genetic alterations have been instrumental in advancing the understanding of the molecular mechanisms of lung cancer pathogenesis and in the development of targeted therapeutics that are effective specific types of oncogene-driven lung cancer. Our laboratory has generated and characterized well over 30 conditional transgenic mice alleles that have inducible expression of each of the characterized lung cancer relevant oncogenic drivers. We have also created a repository of over 50 genomically annotated NSCLC lines, which can be used for conventional xenograft studies. More importantly, these GEM and standard xenograft lung cancer models have been employed successfully in multiple efficacy and pharmacodynamics studies with novel therapeutics that target genetically defined oncogenic drivers or their downstream effector pathways. In addition, our laboratory are in the process of generating and characterizing lung cancer PDX models derived from patient resected/biopsy samples at DFCI. The appropriate EGFR, KRAS, and other-genotype specific GEM, PDX and xenograft models will be used for each of the projects described in this P01 proposal. Overall the Animal Modeling and Preclinical Therapeutics Core will facilitate the preclinical discoveries that enable clinical translation with the ultimate goal of improving lung cancer outcomes.

Public Health Relevance

The Animal Core (Core C) aims to use genetically engineered mouse (GEM) lung cancer models, human lung cancer cell line xenografts, and patient derived xenograft (PDX) models of lung cancer to elucidate mechanisms of lung cancer pathogenesis, to validate therapeutic targets, to determine in vivo therapeutic efficacy and to elucidate in vivo mechanisms of acquired resistance, for all three Projects in this Program. The core serves three specific purposes: a) a high-tech core and intellectual resource to perform and assist with all aspects of in vivo experiments; b) an innovative research core to develop new genetically engineered mouse models based on genetic alterations and deregulated pathways validated in vitro from all three Projects and c) generation of annotated PDX from lung cancer patients at the time of diagnosis and at time of relapse from various novel therapeutic treatments relevant to all three Projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA154303-09
Application #
10003967
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2012-05-11
Project End
2022-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
9
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233
Terai, Hideki; Kitajima, Shunsuke; Potter, Danielle S et al. (2018) ER Stress Signaling Promotes the Survival of Cancer ""Persister Cells"" Tolerant to EGFR Tyrosine Kinase Inhibitors. Cancer Res 78:1044-1057
Rusan, Maria; Li, Kapsok; Li, Yvonne et al. (2018) Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discov 8:59-73
Adeegbe, Dennis O; Liu, Shengwu; Hattersley, Maureen M et al. (2018) BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res 6:1234-1245
Gannon, Hugh S; Zou, Tao; Kiessling, Michael K et al. (2018) Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. Nat Commun 9:5450
Aguirre, Andrew J; Hahn, William C (2018) Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers. Cold Spring Harb Perspect Med 8:
Rowbotham, S P; Li, F; Dost, A F M et al. (2018) H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat Commun 9:4559
Tan, Li; Gurbani, Deepak; Weisberg, Ellen L et al. (2017) Structure-guided development of covalent TAK1 inhibitors. Bioorg Med Chem 25:838-846
Tan, Li; Gurbani, Deepak; Weisberg, Ellen L et al. (2017) Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. Bioorg Med Chem 25:1320-1328
Adeegbe, Dennis O; Liu, Yan; Lizotte, Patrick H et al. (2017) Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov 7:852-867

Showing the most recent 10 out of 80 publications